BlossomHill Therapeutics, Inc. (NASDAQ:BLSM)
| Market Cap | 639.79M+37.5% |
| Revenue (ttm) | 0 |
| Net Income | -21.01M |
| EPS | -0.72 |
| Shares Out | 29.08M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 136,285 |
| Open | 23.00 |
| Previous Close | 22.93 |
| Day's Range | 21.82 - 23.17 |
| 52-Week Range | 15.25 - 23.37 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | 33.67(+53.05%) |
| Earnings Date | n/a |
About BLSM
Blossomhill Therapeutics, Inc. is a biopharmaceutical company. It engages in the development of small molecule medicines for unmet medical needs in cancer treatment. The company was founded in June 2020 and is headquartered in San Diego, CA.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$BLSM stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in BLSM holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by BLSM's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
BLSM Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New BLSM patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to BLSM from public contracts
Source: USAspending.gov
BLSM Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from BLSM’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score